

POLYPEPTIDE GROUP AG CHF0.01

ISIN: CH1110760852 WKN: 111076085

Overview

2024/10/18 17:30:09

Price
29.75 CHFDifference  -0.67% (-0.20)

General attributes

| | |
|----------------|--------------------|
| ISIN | CH1110760852 |
| Symbol | PPGN |
| Exchange | SIX Swiss Exchange |
| Currency | CHF |
| Sector | Other |
| Security type | Stock |
| Market cap (m) | 1,046 EUR |
| Benchmark | SWISS MARKET INDEX |

Market data

| | |
|-------------------|-----------------|
| Bid (Bid size) | 29.75 CHF (478) |
| Ask (Ask size) | 29.80 CHF (231) |
| Open | 30.20 CHF |
| High | 31.00 CHF |
| Low | 29.70 CHF |
| Close (prev. day) | 29.95 CHF |
| VWAP | 30.110453 CHF |
| Volume (pcs) | 21,867 |
| Trading volume | 658,425.28 |
| Number of trades | 293 |
| Last size | 1 |


Futures and Options

| | |
|-----------------|-----|
| Related Futures | - |
| Related Options | 360 |

PDF Downloads

Company report: POLYPEPTIDE
GROUP AG CHF0.01 

5Y

Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research

| on sector | on market | | |
|------------|---|-----------------------|---|
| Date | | Headline | Download |
| 2024/09/27 |  | Global Equity Ratings |  |
| 2024/09/11 |  | Global Equity Ratings |  |
| 2024/09/05 |  | Global Equity Ratings |  |
| 2024/08/12 |  | Global Equity Ratings |  |
| 2024/07/24 |  | Global Equity Ratings |  |

Details

2024/10/18 17:30:09

Price

29.75 CHF

Difference  -0.67% (-0.20)

General attributes

| | |
|----------------|--------------------|
| ISIN | CH1110760852 |
| Symbol | PPGN |
| Exchange | SIX Swiss Exchange |
| Currency | CHF |
| Sector | Other |
| Security type | Stock |
| Market cap (m) | 1,046 EUR |
| Benchmark | SWISS MARKET INDEX |


Market data

| | |
|-------------------|-----------------|
| Bid (Bid size) | 29.75 CHF (478) |
| Ask (Ask size) | 29.80 CHF (231) |
| Open | 30.20 CHF |
| High | 31.00 CHF |
| Low | 29.70 CHF |
| Close (prev. day) | 29.95 CHF |
| VWAP | 30.110453 CHF |
| Volume (pcs) | 21,867 |
| Trading volume | 658,425.28 |
| Number of trades | 293 |
| Last size | 1 |

Performance and Risk

| | 6m | 1Y | 3Y |
|-------------|--------|---------|---------|
| Perf (%) | +1.88% | +75.31% | -75.04% |
| Perf (abs.) | +0.55 | +12.78 | -89.45 |
| Beta | 1.41 | 1.37 | 1.36 |
| Volatility | 39.85 | 46.19 | 65.61 |

5Y



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

| | |
|---|------------------------|
| Ø price 5 days Ø volume 5 days (pcs.) | 28.92 CHF (16,722) |
| Ø price 30 days Ø volume 30 days (pcs.) | 30.28 CHF (19,962) |
| Ø price 100 days Ø volume 100 days (pcs.) | 30.87 CHF (26,003) |
| Ø price 250 days Ø volume 250 days (pcs.) | 25.21 CHF (39,507) |
| YTD High date | 35.80 CHF (2024/08/13) |
| YTD Low date | 14.11 CHF (2024/01/22) |
| 52 Weeks High date | 35.80 CHF (2024/08/13) |
| 52 Weeks Low date | 14.11 CHF (2024/01/22) |

All listings for POLYPEPTIDE GROUP AG CHF0.01

| Exchange  | Date | Time | Price | Trading volume (mio.) | Number of trades |
|--|------------|-------|-----------|-----------------------|------------------|
| SIX Swiss Exchange | 2024/10/18 | 17:30 | 29.75 CHF | 0.66 | 293 |
| London Stock Exchange | 2024/05/07 | 13:59 | 31.25 CHF | 0.30 | 1 |
| FINRA other OTC Issues | - | - | - | 0.00 | 1 |

Company profile

Company Logo

Contact Details

POLYPEPTIDE GROUP AG

--

Neuhofstrasse 24 - 6340 Baar

Telefon: +41-43-502-05-80

Fax: +

E-mail: info@polypeptide.com

PDF Downloads

Company report: POLYPEPTIDE
GROUP AG CHF0.01



Company Profile

PolyPeptide Group AG engages in the business of development, manufacturing, and marketing of peptide- and oligonucleotide-based compounds for use in the pharmaceutical and related research industries. It operates through the following business areas: Custom Projects, Contract Manufacturing, and Generics and Cosmetics. The Custom Projects business area includes manufacturing of custom research-grade peptides and oligonucleotides for use in pre-clinical and clinical development as well as for regulatory and scientific studies. The Contract Manufacturing business area focuses on peptides for commercial stage peptide therapeutics, at scale, in commercial batches and in accordance with current Good Manufacturing Practice (cGMP) requirements. The Generics and Cosmetics business area is involved in peptide-based generics for the human and veterinary market, produced on an industrial scale following cGMP guidelines. The company was founded in 1996 and is headquartered in Zug, Switzerland.

Members of Management Board

| | |
|-----------------------|-------------------------------|
| Juan-José Gonzalez | Chairman of Managing Board |
| Christina del Vecchio | Member of Executive Committee |
| Jens Fricke | Member of Executive Committee |
| Marc Augustin | Member of Executive Committee |
| Neil Thompson | Member of Executive Committee |
| Stéphane Varray | Member of Executive Committee |

Board of directors

| | |
|-------------------|--------------------------------------|
| Beat In-Albon | Member of the administrative board |
| Jane Salik | Member of the administrative board |
| Patrick Aebischer | Member of the administrative board |
| Philippe Weber | Member of the administrative board |
| Erik Schropp | Member of the administrative board |
| Peter Wilden | Chairman of the administrative board |